|
Market Closed -
Euronext Paris
12:55:00 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 18.50 EUR | -2.12% |
|
+3.06% | -38.94% |
| 09-17 | Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-22 | Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Business description: BOIRON
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (43.5%), Europe (24%), North America (27.5%) and other (5%).
Number of employees: 2,623
Sales by Activity: BOIRON
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
Manufacture and Marketing of Homeopathic Medicines & Other Healthcare Solutions | 455M | 534M | 493M | 488M | 501M |
Geographical breakdown of sales: BOIRON
| Fiscal Period: December | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) | 2025 (EUR) |
|---|---|---|---|---|---|
France | 327M | 395M | 342M | 341M | 344M |
North America | 83.91M | 121M | 121M | 126M | 138M |
Europe (excluding France) | 112M | 126M | 123M | 124M | 121M |
Other Countries | 10.2M | 15.12M | 16.28M | 21.97M | 27.24M |
Eliminations | -77.46M | -123M | -109M | -126M | -130M |
Executive Committee: BOIRON
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Houdayer
CEO | Chief Executive Officer | 57 | 2024-12-31 |
Frédéric Riou
CTO | Chief Tech/Sci/R&D Officer | - | - |
Isabelle Chanel
CTO | Chief Tech/Sci/R&D Officer | - | 2021-12-31 |
Hervé Coulpier
CTO | Chief Tech/Sci/R&D Officer | - | 2017-04-30 |
Patrice Varraut
COO | Chief Operating Officer | - | 2015-12-31 |
Composition of the Board of Directors: BOIRON
| Director | Title | Age | Since |
|---|---|---|---|
Thierry Boiron
CHM | Chairman | 65 | 2011-06-30 |
| Director/Board Member | 54 | 2010-03-09 | |
| Director/Board Member | 51 | 2013-05-22 | |
Grégory Walter
BRD | Director/Board Member | 48 | 2017-05-17 |
| Chairman | 48 | 2024-07-02 | |
Laurence Boiron
BRD | Director/Board Member | 51 | 2020-05-27 |
Sylvain Mossaz
BRD | Director/Board Member | 50 | 2020-12-16 |
Philippe Brun
BRD | Director/Board Member | 66 | 2021-05-26 |
Jean-Marc Chalot
BRD | Director/Board Member | 67 | 2022-05-18 |
Pascal Houdayer
BRD | Director/Board Member | 57 | 2024-12-31 |
Holdings: BOIRON
| Name | Stocks | % | Valuation |
|---|---|---|---|
BOIRON 1.04% | 183,133 | 1.04% | 4 M $ |
Company details: BOIRON
Group companies: BOIRON
| Name | Category and Sector |
|---|---|
Boiron Laboratories Pvt Ltd. |
Alternative Medicine
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.12% | +3.06% | -32.85% | -53.40% | 366M | |
| +0.50% | +1.38% | +57.09% | +129.96% | 1,143B | |
| +0.86% | +5.14% | +45.00% | +86.15% | 647B | |
| -0.14% | +0.42% | +25.69% | +105.85% | 506B | |
| -0.05% | +1.73% | +52.74% | +67.74% | 384B | |
| -0.63% | -5.97% | +61.93% | +37.06% | 350B | |
| +0.34% | +1.84% | +30.70% | +54.27% | 293B | |
| -0.45% | +1.19% | +2.89% | +26.08% | 265B | |
| +0.87% | +3.08% | +54.69% | +72.74% | 242B | |
| +0.08% | +3.67% | +35.05% | +107.78% | 197B | |
| Average | -0.07% | +1.61% | +33.29% | +63.42% | 402.79B | |
| Weighted average by Cap. | +0.25% | +1.55% | +44.49% | +89.00% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- BOI Stock
- Company BOIRON
Select your edition
All financial news and data tailored to specific country editions
